Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan, China

Xingsheng Hu¹, Chunhong Hu¹, Dixuan Jiang², Qian Zuo³, Ya Li⁴, Yang Wang⁵, and Xiangyu Chen⁴

Abstract

Objective: To investigate clinical efficacy and safety of convalescent plasma (CP) therapy in coronavirus disease 2019 (COVID-19) patients.

Methods: We included 4 severe patients and 3 critical patients. The date of admission to hospital ranged from January 30 to February 19, 2020. We retrospectively collected clinical and outcome data. Relative parameters were compared.

Results: After CP therapy, the symptoms and respiratory functions were improved. Median PaO2/FIO2 increased from 254 (142-331) to 326 (163–364), and dependence of oxygen supply decreased. Median time to lesion’s first absorption was 5 (2–7) days, undetectable viral RNA was 11 (3.5–15.7) days. Median lymphocyte count (0.77 × 10⁹/L vs 0.85 × 10⁹/L) and albumin level (31g/L vs 36 g/L) were elevated, C-reactive protein (44 mg/L vs 18 mg/L), D-dimer (5.9 mg/L vs 4 mg/L) and lactate dehydrogenase (263 U/L vs 245 U/L) decreased. No obvious adverse reactions were observed. At the follow-up on June 14, 2020, 6 patients had completely recovered and one died from terminal disease.

Conclusion: CP therapy for COVID-19 was effective and safe. Three patients who did not combine with antiviral therapy after CP also obtained viral clearance and clinical improvement. However, CP therapy failed to save the life of a terminally ill patient.

Keywords
COVID-19, SARS-CoV-2, convalescent plasma, PaO2/FIO2, clinical outcomes

Introduction

Coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)¹ that emerged in Wuhan, China in December 2019, and rapidly spread around the world. By Aug 6, 2020, COVID-19 had spread to >200 countries, caused >21 million infections, and 761 779 deaths,² and these figures are still increasing.

There were no new drugs or vaccines, and most of the antiviral therapies were derived from experience of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and included interferon, lopinavir/ritonavir, arbidol, and chloroquine.³ However, a recent clinical trial in Wuhan showed that addition of lopinavir/ritonavir to standard care did not significantly improve clinical prognosis or clearance of viral RNA.⁴ A trial initiated on April 29, 2020 showed that remdesivir significantly shortened the recovery time from COVID-19, but it did not significantly reduce mortality rate

¹ Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, People’s Republic of China
² Department of Respiratory Medicine, The First Hospital of Changsha City, Changsha, Hunan, People’s Republic of China
³ Department of Radiology, The First Hospital of Changsha City, Changsha, Hunan, People’s Republic of China
⁴ Department of Radiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China
⁵ Department of Pathology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, People’s Republic of China

Received 17 August 2020; received revised 17 November 2020; accepted 17 November 2020

Corresponding Authors:
Yang Wang, Department of Pathology, The Second Xiangya Hospital of Central South University, 410011 Changsha, Hunan, People’s Republic of China. Email: wangyang@csu.edu.cn
Xiangyu Chen, Department of Radiology, The Second Xiangya Hospital of Central South University, 410011 Changsha, Hunan, People’s Republic of China. Email: chenxiangyu@csu.edu.cn

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
compared with the placebo group. Convalescent plasma (CP) therapy was approved by the Chinese Government and US Food and Drug Administration (FDA), owing to its success in the SARS, MERS and influenza A (H1N1) pandemics. A meta-analysis, which included 2 studies of SARS, 5 of H1N1 and one of H5N1, showed that convalescent plasma or serum compared with placebo or no therapy significantly reduced mortality risk (odds ratio = 0.25; P < 0.001). In nearly 2 months, between Mar. 2020 and Apr. 2020, 2 studies and 3 case reports of CP therapy of COVID-19 were published; all of which displayed clinical efficacy. Here, we describe our results of CP therapy of COVID-19.

Methods

Patients and Ethics

Patients came from Changsha Public Health Treatment Center of Hunan Province, which was one of the main treatment centers for COVID-19 in the local area. Inclusion criteria: (1) inpatients with laboratory-confirmed COVID-19, who received CP therapy; and (2) available clinical and outcomes data. This study was approved by the Institutional Review Board and Ethics Commission of The Second Xiangya Hospital (2020017). Written informed consent was waived by the Ethics Commission of the designated hospital for retrospective analysis and emerging infectious diseases.

Data Collection

We retrospectively collected patient data from the above medical centers. The date of hospital admission ranged from January 30 to February 19, 2020. The date of discharge/transfer ranged from March 4 to 14, 2020. The data included the basic epidemiological and clinical features, especially the time of CP therapy, improvement of symptoms, oxygen supply, and radiological and laboratory parameters.

Diagnosis of COVID-19

COVID-19 was diagnosed according to the “Diagnosis and Treatment Protocol for Novel Coronavirus Infection-Induced Pneumonia, version 7.” Confirmation was based on the following: (1) real-time reverse transcription polymerase chain-reaction (RT-PCR), and nucleic acid test of respiratory or blood specimens were positive; and (2) high-throughput gene sequencing was highly homologous with SARS-CoV-2 in respiratory or blood specimens. RT-PCR assays were performed in accordance with the protocol established by the World Health Organization (WHO).

Clinical Classification and Definitions

The clinical classification of patients was evaluated according to the “Diagnosis and Treatment Protocol for Novel Coronavirus Infection-Induced Pneumonia version 7.” Severe disease (one of the following conditions): I, respiratory rate ≥30 breaths/min; II, oxygen saturation ≤93% at rest; III, partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ≤300 mmHg; IV, developed rapidly on radiological findings within 24-48 hours. Critical criteria (one of the following conditions): I, respiratory failure and a requirement for mechanical ventilation; II, shock; III, combined failure of other organs and requirement for intensive care unit monitoring and treatment.

Results

Clinical Characteristics

We enrolled 4 severe patients and 3 critical patients. The median age was 64 (57–70) years; median time from onset of
symptoms to hospital admission was 8 (4–20) days; median time from hospital admission to receiving CP transfusion was 23 (8–27) days; and median time from CP transfusion to discharge was 13 (10–16) days. Just before transfusion, 1 patient had low white cell count, 1 had high white cell count, 5 had high neutrophil proportion and low lymphocyte count, 2 had high aminotransferase levels, 1 had high creatinine, 6 had high D-dimer, 3 had high lactate dehydrogenase (LDH), and all of them had high C-reactive protein (CRP). Three patients were considered to combine with lung abscess. Except Patient 5 did not combine antibiotic therapy before (10 days)/after transfusion, all of other patients received antibiotic therapy before/after transfusion. Except Patients 3, 5 and 7, and Patient 2 (stopped just 1 day after transfusion), all other patients received antiviral therapy after CP transfusion. The clinical characteristics before transfusion are presented in Table 1, and parameters just before transfusion are presented in Tables 2 and 3.

**Improvement of Clinical and Laboratory Parameters After CP Therapy**

The improvement of several primary parameters within 1, 4, 7, 10 and 20 days (all of the patients discharged/transferred out) after transfusion are presented in Table 2 and Figure 1, and other laboratory parameters in Table 3. After transfusion, symptoms of all patients were improved. The median PaO2/FIO2 increased from 254 (142–331) to 326 (163–364), although the median SPO2 level remained at 96%, 5 patients were tested with no oxygen supply after transfusion. Although Patient 3 received invasive mechanical ventilation after transfusion, she transferred to noninvasive mechanical ventilation and was weaned from extracorporeal membrane oxygenation before transferring out. Patient 2 was weaned from high-flow nasal cannula to discontinued low-flow nasal cannula oxygen supply, and other 4 patients were weaned from low-flow nasal cannula oxygenation to stopping oxygen supply. After CP therapy, improvement of CT/X-ray findings was observed at different periods (Figures 2 and 3). The median time of first absorption was 5 (2–7) days. Before transfusion, except Patient 7, all of other patients were positive for detection of SARS-CoV-2 RNA. After transfusion, SARS-CoV-2 RNA in all 6 patients became undetectable within 2–21 days [median 11 (3.5–15.7) days]. After CP therapy, 5 of 7 patients showed elevation of lymphocyte count (median: 0.77 × 10⁹/L vs 0.85 × 10⁹/L), and 5 of 6 patients showed elevation of albumin (median: 31 g/L vs 36 g/L). The inflammatory indicators CRP and erythrocyte sedimentation rate (ESR) decreased markedly (median: 44 mg/L vs 18 mg/L) and (median: 113 mm/h vs 66 mm/h), respectively. D-dimer (median: 5.9 mg/L vs 4 mg/L) and LDH (median: 263 U/L vs 245 U/L) also decreased. Elevated temperature and alanine aminotransferase decreased to normal in 2 patients, and procalcitonin level in 2 patients and lactic acid level in 3 patients also decreased. No obvious adverse effects were observed, such as fever, allergic reaction, elevation of liver and kidney function, or acute lung injury.

**Follow-Up and Prognosis**

On the follow-up of March 15, 2020, all patients were discharged/transferred out because of negative detection of viral RNA on continuous 2 or 3 occasions. Patients 1 and 5 were discharged with complete recovery. Patients 2, 4 and 6 were transferred to the general hospital for comorbidity. All of them recovered. Patient 4 was discharged on April 3, 2020, patient 6 on March 19, 2020, but the date for Patient 2 is unclear. Patient 3 and Patient 7 was transferred out for integrated treatment on March 14, 2020 and March 10, 2020 respectively. Patient 7 died at March 10, 2020 because of MODS. At June 14, 2020 patient 3 was discharged for complete recovery. All of patients had at least 3 occasions of continuous negative detection of SARS-CoV-2 by RT-PCR after discharge.

**Discussion**

Nearly 2 decades ago, CP was successfully used to treat SARS and H1N1. Soo et al. reported patients with SARS who deteriorated after ribavirin and methylprednisolone therapy.8 The CP therapy group (n = 19) compared with the steroid therapy group (n = 21) had a higher discharge rate by 22 days (74% vs 19%, P = 0.001) and lower mortality rate (0% vs 23.8%, P = 0.049). Another study showed that CP therapy reduced mortality of SARS compared with the statistical data in the same period (12.5% vs 17%) in Hong Kong.24 Similar results were found for H1N1.10,25 One study showed that mortality in the CP group was 20.0% compared with 54.8% in the non-CP group (P = 0.011).10 Two of 3 patients with MERS showed neutralizing activity after receiving CP therapy.9 However, in Ebola virus disease, CP therapy did not significantly reduce mortality rate (31% vs 38%, P > 0.05).26 The reason was unknown, and may have been due to absence of detection of antibody titer, or using a historical control group, or other confounding factors. Nevertheless, the use of CP therapy in Ebola is recommend by WHO.27

In this study, we evaluated the efficacy and safety of CP therapy in 7 patients with COVID-19. After CP therapy, clinical manifestations of all patients were improved, and respiratory function was elevated, as assessed by improved PaO2/FIO2 and SPO2. The dependence of oxygen supply was decreased. One patient was weaned from invasive to noninvasive mechanical ventilation; another was transferred from high-flow nasal cannula oxygenation to discontinued low-flow nasal cannula oxygenation; and 4 patients no longer needed oxygen therapy. After CP therapy, lesions detected by CT/X-ray were gradually absorbed and viral RNA gradually became undetectable. Most interestingly, 3 patients did not receive antiviral drugs after CP therapy (1 patient stopped antiviral drugs just 1 day after CP therapy), and all of them achieved viral clearance and clinical improvement.

Several primary laboratory parameters were also improved after CP therapy. Previous studies showed lower lymphocyte count and albumin level, and increased CRP, D-dimer and LDH, and all patients were associated with poor prognosis of
Table 1. Clinical Characteristics of Patients.

| Variables                        | Patient 1       | Patient 2       | Patient 3       | Patient 4       |
|----------------------------------|-----------------|-----------------|-----------------|-----------------|
| Sex                              | Female          | Male            | Female          | Male            |
| Ages                             | 64              | 64              | 66              | 57              |
| Smoking                          | No              | No              | No              | No              |
| Days from symptom onset to admission | 5              | 20              | 2               | 30              |
| Days from admission to transfusion | 8              | 1               | 24              | 14              |
| Date of transfusion              | Feb. 19         | Feb. 20         | Feb. 27         | Feb. 27         |
| Days from transfusion to discharge | 20             | 12              | 15              | 14              |
| Coexisting disease               | CHD, cirrhosis, gastric varices, diabetes, pancytopenia | CHD, heart failure | No              | No              |
| Clinical classification           | Severe          | Critical        | Critical        | Severe          |
| Complications                    | Bacterial pneumonia | Hydrothorax, hydropericardium, liver injury, PTE, multiple vein thrombus | Bacterial pneumonia, ARDS, fungal infection? | Bacterial pneumonia, ARDS, fungal infection? |
| Pre-transfusion Complications     | Ditto           | Ditto + bacterial pneumonia | Ditto + PTE, class III atrioventricular block, shock, septicopyemia | Ditto (no ARDS) |
| Drugs therapy                    | LPV/r Feb.11-Feb.18, interferon-α Feb.11-Feb.25, arbidol Mar.5-Mar.13, chloroquine Feb.20-Feb.27 | Arbidol Feb.19-Feb.21 | Arbidol Feb.3-Feb.11, LPV Feb.11-Feb.18 | LPV/r Feb.13-Feb.19, arbidol Feb.16-Feb.26, interferon-α Feb.13-Mar.6 |
| Antiviral drugs                   | Moxifloxacin Feb.11-Feb.18, PIP/TAZ Feb.22-Mar.2 | PIP/TAZ Feb.22-Mar.4 | Meropenem Feb.27-Mar.2, voriconazole + Tigecycline Mar.2-Mar.7, daptomycin Mar.4-Mar.7, linezolid + PIP/TAZ Mar.7-Mar.14 | Voriconazole Feb.23-Feb.27, meropenem Feb.25-Mar.2, meropenem Mar.5-Mar.13, Cefperazone-Sulbactam Mar.2-Mar.5, voriconazole Feb.27-Mar.13 |
| Antibiotic⁴                      |                 |                 |                 |                 |
| Steroid                          |                 |                 |                 |                 |
| Pre-transfusion                   | Intermittent    | No              | Intermittent    | Intermittent    |
| Posttransfusion                   | No              | No              | Intermittent    | No              |
| Other main therapies              | No              | No              | CRRT Mar.3-Mar.13 | No              |

(continued)
COVID-19. In our study, after CP therapy, lymphocyte count increased (0.77 \times 10^9/L to 0.85 \times 10^9/L), although this increase seems mild (Patient 1 had combined chronic pancytopenia). Most of severe/critical patients have combined serious lymphocytopenia owing to immune injury by the virus. Our result was consistent with the study of Duan et al. (lymphocyte count: 0.65 \times 10^9/L to 0.76 \times 10^9/L). COVID-19 is associated with a serious inflammation reaction, but after CP therapy, CRP and ESR decreased markedly, which demonstrates that CP may reduce the cytokine storm. We also want to display the change of these inflammation markers, but they were not the routine examinations in our hospital.

The mechanism of CP therapy was main supply neutralizing antibody, which displayed the function of viral clearance. The titers of neutralizing antibody in our study ranged from 1:320 to 1:1280, which exceeded the level of previous study (\geq 1:160). Our result was consistent with the study of Duan et al. (lymphocyte count: 0.65 \times 10^9/L to 0.76 \times 10^9/L).13 COVID-19 is associated with a serious inflammation reaction, but after CP therapy, CRP and ESR decreased markedly, which demonstrates that CP may reduce the cytokine storm. We also want to display the change of these inflammation markers, but they were not the routine examinations in our hospital.

The mechanism of CP therapy was main supply neutralizing antibody, which displayed the function of viral clearance. The titers of neutralizing antibody in our study ranged from 1:320 to 1:1280, which exceeded the level of previous study (\geq 1:160).10,24 In the previous study in COVID-19,12,13 after CP transfusion, the elevation of antibody titers in receivers were also observed. Owing to this study was a retrospective study, we did not obtain the record of antibody titer in receivers, as far as our best endeavor.

There are several key challenges and problems that needed to be addressed. (1) Owing to the shortage of CP and emergency nature of COVID-19, it is difficult to carry out randomized controlled trials. (2) Time of collection of CP. Previous study of SARS showed that neutralizing antibody titers reached a peak at 4 months,29 IgG titers increased to an average of 1:256 at week 3 and reached a peak at 3–4 months.29,30 So the time of collection of CP is important. (3) Therapeutic antibody titers. In previous studies of SARS and H1N1,9,10 the range of neutralizing antibody titers was above 1:160. Whether antibodies display a therapeutic effect at titers below 1:160 is still unknown. (4) Time of transfusion. A previous study showed that the efficacy of CP therapy was better before than after day 14 in SARS patients.24 However, in COVID-19, Shen et al.12 and Duan et al.13 showed that a transfusion time >14 days was effective. In a previous study, the median viral shedding time was 20 days (the longest was 37 days) after onset of symptoms.

### Table 1. (continued)

| Variables | Patient 5 | Patient 6 | Patient 7 |
|-----------|-----------|-----------|-----------|
| Date of transfusion | Feb. 27 | Feb. 27 | Mar. 7 |
| Days from transfusion to discharge | 12 | 12 | 3 |
| Coexisting disease | No | No | Hypertension, diabetes |
| Clinical classification | Severe | Severe | Critical |
| Complications Pre-transfusion | Bacterial pneumonia, ARDS | Bacterial pneumonia, lung abscess, ARDS, fungal infection? | Bacterial pneumonia, septicemia, GIB, anemia, renal failure, shock, ARDS, MODS, fungal infection? |
| Drugs therapy Posttransfusion | Ditto (no ARDS) | Ditto (no ARDS) | Ditto |
| Antiviral drugs | LPV/r Feb. 5-Feb. 17, arbidol Feb. 7-Feb. 23, interferon-\(\alpha\) Feb. 17-Feb. 25 | LPV/r Jan. 30-Feb. 13, arbidol Mar. 6-Mar. 11, interferon-\(\alpha\) Feb. 19-Mar. 11, chloroquine Feb. 19-Feb. 27 | LPV/r Feb. 4-Feb. 18, arbidol Feb. 25-Mar. 1 |
| Antibiotic\(^d\) | Moxifloxacin Feb. 5-Feb. 15, PIP/TAZ Feb. 17-Feb. 18 | PIP/TAZ Feb. 24-Feb. 28 meropenem Feb. 28-Mar. 5, linezolid + voriconazole Mar. 2-Mar. 11 | Meropenem Mar. 7-Mar. 9, daptomycin Mar. 7-Mar. 9, voriconazole Feb. 25-Mar. 9, caspofungin Feb. 25-Mar. 9 |
| Steroid Pre-transfusion | Intermittent | Intermittent | Intermittent |
| Posttransfusion | No | No | No |
| Other main therapies | CRRT Feb. 26-Mar. 9 | CRRT Feb. 26-Mar. 9 | CRRT Feb. 26-Mar. 9 |

\(^d\) The latest time or posttransfusion.

CHD: Coronary heart disease; PTE: Pulmonary Thromboembolism; ARDS: Acute respiratory distress syndrome; GIB: Gastrointestinal Bleeding; MODS: Multiple organ dysfunction syndrome; LPV/r: Lopinavir/ritonavir; PIP/TAZ: Piperacillin-tazobactam; CRRT: Continuous renal replacement therapy.
### Table 2. Improvement of Clinical Features and Primary Laboratory Parameters After CP Therapy.

| Variables                               | Patient 1                          | Patient 2                          | Patient 3                          | Patient 4                          |
|-----------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
| **Respiratory symptoms**                |                                    |                                    |                                    |                                    |
| Just pre-transfusion                    | Cough, dyspnea                      | Cough, expectoration, dyspnea       | Cough, expectoration, dyspnea       | Cough, expectoration, dyspnea, hemoptysis |
| Day 1 posttransfusion                   | Dyspnea alleviation                | Above symptoms alleviation          | Ditto                              | Ditto                              |
| Day 4 posttransfusion                   | Ditto                              | Continuous alleviation              | Lack record (owing to mechanical ventilation) | Ditto                              |
| Day 7 posttransfusion                   | Cough alleviation                   | Continuous alleviation              | Lack record                        | Ditto                              |
| Day 10 posttransfusion                  | No symptoms                        | Continuous alleviation              | Lack record                        | Ditto                              |
| Day20* posttransfusion                  | No symptoms                        | No symptoms                        | No respiratory distress after tube drawing | No symptoms                        |
| **Oxygen supply**                       |                                    |                                    |                                    |                                    |
| Just pre-transfusion                    | Low-flow nasal cannula             | High-flow nasal cannula             | High-flow nasal cannula^b          | Low-flow nasal cannula             |
| Day 1 posttransfusion                   | Low-flow nasal cannula             | High-flow nasal cannula             | High-flow nasal cannula^b          | Ditto                              |
| Day 4 posttransfusion                   | Intermittent oxygenation           | Low-flow nasal cannula              | Invasive ventilation               | Ditto                              |
| Day 7 posttransfusion                   | Ditto                              | Ditto                              | Invasive ventilation + ECMO (day 5) | Ditto                              |
| Day 10 posttransfusion                  | Ditto                              | Ditto                              | Ditto                              | Ditto                              |
| Day 20 posttransfusion                  | Stop oxygenation                   | Intermittent oxygenation            | Non-invasive ventilation, stop ECMO (day 11) | Stop oxygenation                   |
| **PaO2/FIO2**                           |                                    |                                    |                                    |                                    |
| Just pre-transfusion                    | 309                                | 207                                | 152                                | 397                                |
| Day 1 posttransfusion                   | 300                                | 293                                | 144                                | 528                                |
| Day 4 posttransfusion                   | 373                                | 336                                | 80                                 | 437                                |
| Day 7 posttransfusion                   | 315                                | 489                                | 220                                | –                                  |
| Day 10 posttransfusion                  | 315                                | 240                                | 300                                | –                                  |
| Day 20 posttransfusion                  | 330                                | 323                                | 183                                | –                                  |
| **SPO2**                                | 94%                                | 96%                                | 95%                                 | 96%                                 |
| Just pre-transfusion                    | (oxygen 2L/min)                     | (FIO2 45%)                         | (FIO2 45%)                         | (oxygen 2L/min)                     |
| Day 1 posttransfusion                   | 96%                                | 99%                                | 98%                                 | 98%                                 |
| Day 4 posttransfusion                   | 95%                                | 96%                                | 91-94%                             | 98%                                 |
| Day 7 posttransfusion                   | 98%                                | 99%                                | (FIO2 60%)                         | 98%                                 |
| Day 10 posttransfusion                  | 98%                                | 99%                                | (FIO2 35%)                         | 98%                                 |
| Day 20 posttransfusion                  | 98%                                | 95%                                | (FIO2 35%)                         | 98%                                 |
| **CT changes**                          |                                    |                                    |                                    |                                    |
| Just pre-transfusion                    | Bilateral GGO                      | Bilateral GGO, bilateral hydrothorax, hydropericardium | Bilateral GGO, consolidation, Interstitial abnormalities | Bilateral GGO, left cavity |
| Lesion absorption date                  | Day 5, 20                          | Day 2                              | Day 7, 11                          | Day 4, 9                            |
| **SARS-CoV-2 RNA**                      |                                    |                                    |                                    |                                    |
| Just pre-transfusion                    | Positive                           | Positive                           | Positive                           | Positive                           |
| Undetectable date posttransfusion       | Day21, Day22, Day23                | Day2, Day3, Day5                   | Day13, Day14, Day15                | Day14, Day15                        |
| **Lymphocyte (*10^9/L)**                |                                    |                                    |                                    |                                    |
| Just pre-transfusion                    | 0.16                               | 0.37                               | 0.74                               | 0.80                               |
| Day 1 posttransfusion                   | 0.29                               | 0.68                               | –                                  | 0.90                               |
| Day 4 posttransfusion                   | 0.14                               | 0.50                               | 0.94                               | 1.10                               |
| Day 7 posttransfusion                   | 0.17                               | 0.55                               | 1.46                               | –                                  |
| Day 10 posttransfusion                  | 0.20                               | 0.65                               | 0.92                               | 1.50                               |
| Day 20 posttransfusion                  | 0.28                               | 0.68                               | 0.6                                 | 2.00                               |

(continued)
Table 2. (continued)

| Variables          | Patient 1 | Patient 2 | Patient 3 | Patient 4 |
|--------------------|-----------|-----------|-----------|-----------|
| D-dimer (mg/L)     | Just pre-transfusion 5.9 | 13 | 9.18 | 2.2 |
|                    | Day 1 posttransfusion – | – | – | – |
|                    | Day 4 posttransfusion – | 6.8 | 10 | 2.3 |
|                    | Day 7 posttransfusion 6.5 | – | 10 | – |
|                    | Day 10 posttransfusion 7.2 | – | 10 | 1.1 |
|                    | Day 20 posttransfusion 5.0 | – | 4 | 1.3 |
| LDH (U/L)          | Just pre-transfusion 211 | N | 327 | 232 |
|                    | Day 1 posttransfusion 209 | N | – | 255 |
|                    | Day 4 posttransfusion 230 | N | 270 | 206 |
|                    | Day 7 posttransfusion – | N | 277 | – |
|                    | Day 10 posttransfusion 190 | N | 250 | 237 |
|                    | Day 20 posttransfusion – | N | 308 | 245 |
| CRP (mg/L)         | Just pre-transfusion 3.4 | 44 | 76.4 | >80 |
|                    | Day 1 posttransfusion 2.9 | – | – | 54 |
|                    | Day 4 posttransfusion 3.9 | 46 | >80 | 49 |
|                    | Day 7 posttransfusion 1.7 | 75 | >80 | – |
|                    | Day 10 posttransfusion 1.6 | 51 | >80 | 19 |
|                    | Day 20 posttransfusion 1.1 | 53 | 18 | – |
| Albumin (g/L)      | Just pre-transfusion 26 | 34 | 33 | 31 |
|                    | Day 1 posttransfusion – | – | 34 | – |
|                    | Day 4 posttransfusion 27 | 29 | 35 | 41 |
|                    | Day 7 posttransfusion 31 | 30 | 30 | – |
|                    | Day 10 posttransfusion 33 | 31 | 44 | 36 |
|                    | Day 20 posttransfusion 36 | – | 36 | – |

| Variables          | Patient 5 | Patient 6 | Patient 7 | Median c |
|--------------------|-----------|-----------|-----------|----------|
| Respiratory symptoms | Cough, expectoration, dyspnea | Cough, expectoration | Dyspnea | – |
| Day 1 posttransfusion | Above symptoms alleviation | No symptoms | Alleviation | – |
| Day 4 posttransfusion | No symptoms | No symptoms | – | – |
| Day 7 posttransfusion | No symptoms | No symptoms | – | – |
| Day 10 posttransfusion | No symptoms | No symptoms | – | – |
| Day 20 posttransfusion | No symptoms | No symptoms | – | – |
| Oxygen supply       | Low-flow nasal cannula | Low-flow nasal cannula | Invasive ventilation | – |
| Day 1 posttransfusion | Ditto | Ditto | Intermittent nasal cannula | Invasive ventilation |
| Day 4 posttransfusion | Ditto | Ditto | Ditto | Invasive ventilation |
| Day 7 posttransfusion | Ditto | Ditto | Ditto | – |
| Day 10 posttransfusion | Ditto | Ditto | Ditto | – |
| Day 20 posttransfusion | Stop oxygenation | Stop oxygenation | – | – |
| PaO2/FIO2           | Just pre-transfusion 300 | 359 | 111 | 254 (142-331) d |
|                    | Day 1 posttransfusion – | – | 85 | – |
|                    | Day 4 posttransfusion 583 | – | 104 | – |
|                    | Day 7 posttransfusion 355 | – | – | – |
|                    | Day 10 posttransfusion 340 | – | – | – |
|                    | Day 20 posttransfusion – | – | 326 (163-364) |
| SPO2               | Just pre-transfusion 97% (oxygen 2L/min) | 96% (no oxygen supply) | 97% (FIO2 60%) | 96 (95-97) |
|                    | Day 1 posttransfusion 97% (oxygen 2L/min) | 96% | 97% (FIO2 60%) | – |

(continued)
| Variables                          | Patient 5 | Patient 6 | Patient 7 | Median* |
|-----------------------------------|-----------|-----------|-----------|---------|
| Day 4 posttransfusion             | 97%       | 96%       | 95% (FIO2 70%) | –       |
| (oxygen 2L/min)                   |           |           |           |         |
| Day 7 posttransfusion             | 97%       | 96%       | –         | –       |
| (no oxygenation)                  |           |           |           |         |
| Day 10 posttransfusion            | 97%       | 96%       | –         | –       |
| (oxygen 2L/min)                   |           |           |           |         |
| Day 20 posttransfusion            | 97%       | 96%       | – 96 (95-98) | 59.9-120 | 96.3 (95-98) |
| (no oxygenation)                  |           |           |           |         |
| CT changes                        |           |           |           |         |
| Just pre-transfusion              | Bilateral GGO | Bilateral GGO, left cavity | Bilateral GGO, Interstitial abnormalities | – |
| Day 6, 10                         | Day 9     | Day 2     | 5 (2-7) days* |
| posttransfusion                   |           |           |           |         |
| SARS-CoV-2 RNA                    | Positive  | Positive  | Negative  | –       |
| Just pre-transfusion              | Day 4, Day 7, Day 9 | Day 9, Day 11, Day 12 | Day 1, Day 2, Day 3 | 11 (3.5-15.7)$f$ |
| Undetectable date                 |           |           |           |         |
| posttransfusion                   |           |           |           |         |
| Lymphocyte (*10^9/L)              | 0.60      | 1.16      | 1.37      | 0.77 (0.6-1.16) |
| Just pre-transfusion              |           |           |           |         |
| Day 1 posttransfusion             | –         | 1.22      | 1.00      | –       |
| Day 4 posttransfusion             | 0.80      | –         | 0.85      | –       |
| Day 7 posttransfusion             | –         | 2.00      | –         | –       |
| Day 10 posttransfusion            | 1.20      | –         | –         | –       |
| Day 20 posttransfusion            | –         | –         | – 0.85 (0.6-2.0) | – |
| D-dimer (mg/L)                    | 0.87      | 0.21      | 7.9       | 5.9 (0.87-9.18) |
| Just pre-transfusion              |           |           |           |         |
| Day 1 posttransfusion             | –         | 0.61      | 5.8       | –       |
| Day 4 posttransfusion             | Normal    | –         | 10.8      | –       |
| Day 7 posttransfusion             | Normal    | 0.75      | –         | –       |
| Day 10 posttransfusion            | 0.42      | –         | –         | –       |
| Day 20 posttransfusion            | Normal    | –         | –         | 4 (0.75-6.8) |
| LDH (U/L)                         | 263       | Normal    | 337       | 263 (222-332) |
| Just pre-transfusion              |           |           |           |         |
| Day 1 posttransfusion             | –         | –         | 250       | –       |
| Day 4 posttransfusion             | <245      | –         | 420       | –       |
| Day 7 posttransfusion             | –         | –         | –         | –       |
| Day 10 posttransfusion            | <245      | –         | –         | –       |
| Day 20 posttransfusion            | –         | –         | 245 (210-364) | – |
| CRP (mg/L)                        | 35        | 3.3       | >80       | 44 (3.4-80) |
| Just pre-transfusion              |           |           |           |         |
| Day 1 posttransfusion             | –         | 55        | >80       | –       |
| Day 4 posttransfusion             | 32        | –         | >80       | –       |
| Day 7 posttransfusion             | 13        | 8.9       | –         | –       |
| Day 10 posttransfusion            | 7.1       | –         | –         | –       |
| Day 20 posttransfusion            | –         | –         | 18 (7.1-53) | – |
| Albumin (g/L)                     | 30        | 32        | 24        | 31 (26-33) |
| Just pre-transfusion              |           |           |           |         |
| Day 1 posttransfusion             | –         | 35        | –         | –       |
| Day 4 posttransfusion             | 33        | –         | 40        | –       |
| Day 7 posttransfusion             | 34        | –         | –         | –       |
| Day 10 posttransfusion            | –         | –         | –         | –       |
| Day 20 posttransfusion            | 35        | –         | –         | 36 (34-37) |

*aThe last day within 20 days.

*bUsing High flow humidification instrument (40-50L/min).

*cAs for patient 1 to patient 7.

*dExcluding case 6.

*eThe median of first absorption.

$f$ The median of first negative detection RNA, and excluding patient 7.

LDH: Lactate dehydrogenase CRP: C-reactive protein; CT: Computed tomography ECMO: Extracorporeal Membrane Oxygenation; GGO: ground-glass opacity.
### Table 3. Improvement of Other Laboratory Parameters After CP Therapy.

| Variables             | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 |
|-----------------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Temperature (°C)      | N         | N         | N         | 37.4      | N         | N         | 38.2      |
|                       | Just pre-transfusion | N         | N         | N         | 37.4      | N         | N         |
|                       | Posttransfusion     | N         | N         | N         | N         | N         | N         |
| White cell (*10^9/L) | N         | N         | N         | 3.4       | N         | N         | 12.4      |
|                       | Just pre-transfusion | N         | N         | N         | 3.4       | N         | N         |
|                       | Posttransfusion     | 0.94      | 3.8       | N         | N         | N         | N         |
| Neutrophil (%)        | N         | N         | N         | 88%       | N         | 81%       | 77%       |
|                       | Just pre-transfusion | N         | N         | N         | 88%       | N         | 81%       |
|                       | Posttransfusion     | N         | 76%       | 91        | N         | N         | 92        |
| ESR (mm/h)            | N         | N         | N         | 129       | N         | 125       | 115       |
|                       | Just pre-transfusion | N         | 69       | N         | N         | N         | 55        |
|                       | Posttransfusion     | N         | N         | N         | N         | N         | N         |
| ALT (U/L)             | N         | N         | N         | 69        | N         | N         | 57        |
|                       | Just pre-transfusion | N         | 80       | N         | N         | N         | N         |
|                       | Posttransfusion     | N         | N         | N         | N         | N         | N         |
| AST (U/L)             | N         | N         | N         | 162       | N         | N         | 48        |
|                       | Just pre-transfusion | N         | 80       | N         | N         | N         | N         |
|                       | Posttransfusion     | N         | N         | N         | N         | N         | N         |
| Total bilirubin (umol/L) | N         | N         | N         | 110       | N         | N         | 82        |
|                       | Just pre-transfusion | N         | N         | N         | N         | N         | N         |
|                       | Posttransfusion     | N         | N         | N         | N         | N         | N         |
| Creatinine (umol/L)   | N         | N         | N         | 110       | N         | N         | 82        |
|                       | Just pre-transfusion | N         | N         | N         | N         | N         | N         |
|                       | Posttransfusion     | N         | N         | N         | N         | N         | N         |
| PT (s)                | N         | N         | N         | 26        | N         | N         | 19        |
|                       | Just pre-transfusion | N         | 26       | N         | N         | N         | N         |
|                       | Posttransfusion     | N         | 22        | N         | N         | N         | N         |
| APTT (s)              | N         | N         | N         | 58        | N         | N         | N         |
|                       | Just pre-transfusion | N         | 58       | N         | N         | N         | N         |
|                       | Posttransfusion     | N         | 55        | N         | N         | N         | N         |
| Procalcitonin (ug/L)  | <0.05     | <0.05     | 0.07      | 0.1       | <0.05     | <0.05     | 5.3       |
|                       | Just pre-transfusion | <0.05     | <0.05     | 0.07      | 0.1       | <0.05     | <0.05     |
|                       | Posttransfusion     | <0.05     | 0.2       | <0.05     | 0.1       | <0.05     | <0.05     |
| Lactic acid (mmol/L)  | 1.9        | 2        | 2.4       | 2        | 1        | 1.3       | 1.4       |
|                       | Just pre-transfusion | 1.9       | 2        | 2.4       | 2        | 1        | 1.3       |
|                       | Posttransfusion     | 1.4       | 1.2       | 1.3       | 1.4       | 1.3       | 0.9       |

N: Normal; ESR: Erythrocyte sedimentation rate; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; PT: Prothrombin time; APTT: Activated partial thromboplastin time.

**Figure 1.** Laboratory parameters changes before and after CP therapy.
Figure 2. CT changes of patient 1 and patient 4 before and after CP therapy. A, CT of patient 1 obtained on February 16 before CP therapy with local patchy shadowing in right lung and slight ground-glass opacity in bilateral lung. B, CT of patient 1 obtained on February 24 after CP therapy showed the absorption of above lesions after CP therapy. C, CT of patient 4 obtained on February 22 before CP therapy with cavity and exudative lesions. D, CT of patient 4 obtained on March 2 after CP therapy showed the shrunken cavity and exudative lesions.

Figure 3. CT changes of patient 5 and patient 6 before and after CP therapy. A, CT of patient 5 obtained on February 23 before CP therapy with ground-glass opacity in bilateral lung. B, CT of patient 5 obtained on March 4 after CP therapy showed the absorption of above lesions after CP therapy. C, CT of patient 6 obtained on February 24 before CP therapy with ground-glass opacity and consolidative opacities. D, CT of patient 6 obtained on March 7 after CP therapy showed the absorption of above lesions after CP therapy.
in COVID-19, and we also detected viral RNA after 3 weeks of admission.

There were some limitations to our study. (1) Due to the retrospective nature of the study, we did not obtain antibody titers from the recipients of CP. (2) Three patients received combined antiviral therapy after CP, which may have contributed to viral clearance. (3) Six patients received combined antibiotics, which may have contributed to the absorption of CT/X-ray-detected lesions. (4) Because of the shortage of CP sources, the number of patients was small and we did not establish a control group. We used patients self-matching as controls before and after CP transfusion. (5) A small number of patients received CP therapy, therefore, we included all patients who received CP therapy to assess the efficacies in all types of disease status.

In conclusion, this pilot study showed the potential effectiveness and safety of CP therapy in COVID-19, as assessed by improvement of clinical manifestations, respiratory function, viral clearance, other laboratory parameters and long-term follow-up. However, we showed that CP therapy failed to save the life of a terminally ill patient. The limited number of patients and uncontrolled patients preclude definitive conclusions about CP therapy for COVID-19; therefore, clinical trials are needed to determine antibody titers and optimal time of transfusion.

Authors’ Note
The primary data of this article are available from the corresponding author upon reasonable request.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research supported by the Natural Science Foundation of Human Province, NO. 2019J40435.

ORCID iD
Xiangyu Chen  https://orcid.org/0000-0002-4233-8822

References
1. Lu R, Zhao X, Li J, et al. Genomic characterisation and epide-miology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-574.
2. World Health Organization. Published August 17, 2020. Accessed August 17, 2020 https://www.who.int/docs/default-source/coronaviurse/situation-reports/20200816-covid-19-sitrep-209.pdf?sfvrsn=5ddc1ca2_2
3. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60.
4. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787-1799.
5. Back of obtaining of urgent right to use of remdesivir: how to view different outcomes between China and America? Published at May 2, 2020. Accessed May 12, 2020 https://baijiahao.baidu.com/s?id=166557482573807627&wfr=spider&for=pc
6. Notice of issued on convalescent plasma of COVID-19 in clinical treatment plan (version 2). China Hospital Authority. Published March 4, 2020. Accessed June 6, 2020. http://www.nhc.gov.cn/yzygj/s7658/202003/61d608a7e8bf49fca418a6074c2bf5a2.shtml
7. Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020;368:m1256.
8. Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continued high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10:676-678.
9. Ko JH, Seok H, Cho SY, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther. 2018;23(7):617-622.
10. Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52(4):447-456.
11. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. Convales-cent Plasma a Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80-90.
12. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582-1589.
13. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490-9496.
14. Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest. 2020;S0012-3692(1):30571-30577.
15. Ahn JY, Sohn Y, Lee SH, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci. 2020;35(14):e149.
16. Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China [published online April 15, 2020]. J Med Virol. 2020. DOI: 10.1002/jmv.25882.
17. Diagnosis and treatment protocol for novel coronavirus pneumo-nia (version 7). China Government. Published March 3, 2020. Accessed June 6, 2020 http://www.gov.cn/zhengce/zhengceku/2020-03/04/content_5486705.htm
18. World Health Organization. Coronavirus disease (COVID-19) technical guidance: laboratory testing for 2019-nCoV in humans. Published January 24, 2020. Accessed August 17, 2020. https://www.who.int/publications/m/item/molecular-assays-to-diagnose-covid-19-summary-table-of-available-protocols
19. Lu ZY, Zhong NS. Internal Medicine. 7th ed. People’s Health Press; 2009:141.
20. Lu ZY, Zhong NS. Internal Medicine. 7th ed. People’s Health Press; 2009:153.
21. Lu ZY, Zhong NS. *Internal Medicine*. 7th ed. People’s Health Press; 2009:157.
22. Shankar-Hari M, Phillips GS, Levy ML, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315(8):775-787.
23. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. *Nephron Clin Pract*. 2012;120(4):c179-184.
24. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. *Eur J Clin Microbiol Infect Dis*. 2005;24(1):44-46.
25. Luke TC, Kilbane EM, Jackson JL, et al. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? *Ann Intern Med*. 2006;145(8):599-609.
26. Griensven J, Edwards T, Lamballerie X, et al. Ebola-Tx Consortium. Evaluation of convalescent plasma for Ebola virus disease in guinea. *N Engl J Med*. 2016;374(1):33-42.
27. World Health Organization. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. Published September, 2014. Accessed June 6, 2020. http://apps.who.int/iris/rest/bitstreams/604045/retrieve
28. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054-1062.
29. Cao WC, Liu W, Zhang PH, et al. Disappearance of antibodies to SARS-associated coronavirus after recovery. *N Engl J Med*. 2007;357(11):1162-1163.
30. Li G, Chen X, Xu A. Profile of specific antibodies to the SARS-associated coronavirus. *N Engl J Med*. 2003;349(5):508-509.